ATE209909T1 - Verwendung von tachykinin-antagonisten zur behandlung von erbrechen - Google Patents

Verwendung von tachykinin-antagonisten zur behandlung von erbrechen

Info

Publication number
ATE209909T1
ATE209909T1 AT94200691T AT94200691T ATE209909T1 AT E209909 T1 ATE209909 T1 AT E209909T1 AT 94200691 T AT94200691 T AT 94200691T AT 94200691 T AT94200691 T AT 94200691T AT E209909 T1 ATE209909 T1 AT E209909T1
Authority
AT
Austria
Prior art keywords
tachykinin antagonists
antagonists
treat vomiting
vomiting
treat
Prior art date
Application number
AT94200691T
Other languages
English (en)
Inventor
Russell Michael Hagan
Keith Thomas Bunce
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE209909T1 publication Critical patent/ATE209909T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT94200691T 1993-03-19 1994-03-17 Verwendung von tachykinin-antagonisten zur behandlung von erbrechen ATE209909T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939305718A GB9305718D0 (en) 1993-03-19 1993-03-19 Medicaments

Publications (1)

Publication Number Publication Date
ATE209909T1 true ATE209909T1 (de) 2001-12-15

Family

ID=10732372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94200691T ATE209909T1 (de) 1993-03-19 1994-03-17 Verwendung von tachykinin-antagonisten zur behandlung von erbrechen

Country Status (9)

Country Link
US (2) US5547964A (de)
EP (1) EP0615751B1 (de)
JP (2) JPH072658A (de)
AT (1) ATE209909T1 (de)
DE (1) DE69429299T2 (de)
DK (1) DK0615751T3 (de)
ES (1) ES2164684T3 (de)
GB (1) GB9305718D0 (de)
PT (1) PT615751E (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE69404306T2 (de) * 1993-05-28 1997-10-30 Pfizer Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
PT780375E (pt) * 1995-12-21 2002-12-31 Pfizer 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
AU714542B2 (en) * 1996-06-26 2000-01-06 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
CA2352612A1 (en) * 1998-11-27 2000-06-08 Hideo Fukui Pharmaceuticals
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
EP1205855A3 (de) * 2000-11-10 2006-01-25 Masae Yanagi Verfahren, System und Vorrichtung zum Verwalten von Daten, Datenhandlungsgerät, Rechnerprogramm und Speichermedium
EP1756056A1 (de) * 2004-06-08 2007-02-28 Pfizer Products Inc. Aza-bicyclo[3.1.0]hex-1-ylderivate, die als nk1-antagonisten wirken
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
EP2129381A1 (de) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmazeutische zubereitungen enthaltend 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazin or r(-)-2,4-diamino-5-(2,3dichlorophenyl)-6-fluoromethyl pyrimidin und einen nk1- rezeptor-antagonisten
CN105503870A (zh) * 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
WO2020019247A1 (en) * 2018-07-26 2020-01-30 Xw Laboratories, Inc. Compounds as neurokinin-1 receptor antagonists and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048058A (en) * 1975-08-13 1977-09-13 Standard Oil Company (Indiana) Methods to be used in reforming processes employing multi-metallic catalysts
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
FR2610323B1 (fr) * 1987-02-04 1989-06-23 Delalande Sa Enantiomeres de configuration absolue s de derives amide de l'amino-3 quinuclidine, leur procede de preparation et leur application en therapeutique
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
WO1992017449A1 (en) * 1991-03-26 1992-10-15 Pfizer Inc. Stereoselective preparation of substituted piperidines
ES2092113T3 (es) * 1991-06-20 1996-11-16 Pfizer Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
IE72090B1 (en) * 1991-07-05 1997-03-12 Merck Sharp & Dohme Aromatic compounds pharmaceutical compositions containing them and their use in therapy
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
US6329394B1 (en) 2001-12-11
US5547964A (en) 1996-08-20
DE69429299D1 (de) 2002-01-17
JP2000191522A (ja) 2000-07-11
ES2164684T3 (es) 2002-03-01
EP0615751A1 (de) 1994-09-21
DE69429299T2 (de) 2002-10-17
DK0615751T3 (da) 2002-02-18
EP0615751B1 (de) 2001-12-05
GB9305718D0 (en) 1993-05-05
PT615751E (pt) 2002-04-29
JPH072658A (ja) 1995-01-06

Similar Documents

Publication Publication Date Title
DE69429299D1 (de) Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen
ATE209490T1 (de) Substanz p antagonisten zur behandlung von erbrechen
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
FI962350A (fi) BPM-12, BMP-13 sekä niiden jännettä indusoivat koostumukset
ATE206757T1 (de) Thrombin sowie verfahren zu seiner herstellung
DE69735482D1 (de) Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
DE3851584T2 (de) Gegen Allergie wirkende Benzothiophene und neue und andere ausgewählte Benzothiophene, beide mit Wirkung zur Behandlung von akuten Atmungsangstanzeichen.
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ES2072975T3 (es) Mezcla de esterilizante y metodo de esterilizacion.
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE69004924T2 (de) Therapeutische verwendung von 5-ht3-rezeptor-antagonisten.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE3586420T2 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
DE59407576D1 (de) Verwendung von Etofibrat und pharmazeutische Zusammensetzungen, enthaltend Etofibrat, zur Behandlung der diabetischen Angio- und Retinopathie
DE69711422T2 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE163344T1 (de) Zusammensetzungen zur behandlung von geernteter pflanzenmaterial
DE3586321T2 (de) Verwendung von 1,4-dihydropyridinderivaten.
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0615751

Country of ref document: EP